Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

(2015) Ruben A. Mesa et al.   Clinical Lymphoma Myeloma & Leukemia

Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

(2013) Ruben A. Mesa et al.   LEUKEMIA RESEARCH

Assessing Hepatomegaly

(2012) Marius George Linguraru et al.   ACADEMIC RADIOLOGY

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

(2012) O. Benjamini et al.   BLOOD

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD